Genomma Lab Internacional SAB de CV Statistics
Genomma Lab Internacional SAB de CV (GEKA) Stock Statistics & Valuation Metrics
Total Valuation
Genomma Lab Internacional SAB de CV has a market cap or net worth of EUR 746.29M. The enterprise value is EUR 17.56B.
- Market Cap
- EUR 746.29M
- Enterprise Value
- EUR 17.56B
Share Statistics
Genomma Lab Internacional SAB de CV has 1,000,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,000,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- 16.71%
Financial Efficiency
Genomma Lab Internacional SAB de CV’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 12.78%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 12.78%
- Return on Capital Employed (ROCE)
- 0.23
- Revenue Per Employee
- 11.97M
- Profits Per Employee
- 1.10M
- Employee Count
- 1,465
- Asset Turnover
- 0.74
- Inventory Turnover
- 3.54
Valuation Ratios
The current PE Ratio of Genomma Lab Internacional SAB de CV is 8.98. Genomma Lab Internacional SAB de CV’s PEG ratio is -2.30.
- PE Ratio
- 8.98
- PS Ratio
- 0.88
- PB Ratio
- 1.27
- Price to FCF
- 10.76
- Price to Operating Cash Flow
- 9.37
- PEG Ratio
- -2.30
Income Statement
In the last 12 months, Genomma Lab Internacional SAB de CV had revenue of 17.54B and earned 1.61B in profits. Earnings per share was 1.65.
- Revenue
- 17.54B
- Gross Profit
- 11.02B
- Operating Income
- 3.76B
- Pretax Income
- 2.43B
- Net Income
- 1.61B
- EBITDA
- 3.61B
- Earnings Per Share (EPS)
- 1.65
Cash Flow
In the last 12 months, operating cash flow was 1.66B and capital expenditures -260.23M, giving a free cash flow of 1.40B billion.
- Operating Cash Flow
- 1.66B
- Free Cash Flow
- 1.40B
- Free Cash Flow per Share
- 1.39
Dividends & Yields
Genomma Lab Internacional SAB de CV pays an annual dividend of ―, resulting in a dividend yield of 5.12%
- Dividend Per Share
- ―
- Dividend Yield
- 5.12%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.12%
- Earnings Yield
- 10.72%
Stock Price Statistics
- Beta
- 0.35
- 52-Week Price Change
- -9.82%
- 50-Day Moving Average
- 0.64
- 200-Day Moving Average
- 0.73
- Relative Strength Index (RSI)
- 55.60
- Average Volume (3m)
- 25.52K
Important Dates
Genomma Lab Internacional SAB de CV upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 21, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Genomma Lab Internacional SAB de CV as a current ratio of 1.77, with Debt / Equity ratio of 68.64%
- Current Ratio
- 1.77
- Quick Ratio
- 1.52
- Debt to Market Cap
- 0.43
- Net Debt to EBITDA
- 1.33
- Interest Coverage Ratio
- 4.72
Taxes
In the past 12 months, Genomma Lab Internacional SAB de CV has paid 826.24M in taxes.
- Income Tax
- 826.24M
- Effective Tax Rate
- 0.34
Enterprise Valuation
Genomma Lab Internacional SAB de CV EV to EBITDA ratio is 5.64, with an EV/FCF ratio of 14.75.
- EV to Sales
- 1.21
- EV to EBITDA
- 5.64
- EV to Free Cash Flow
- 14.75
- EV to Operating Cash Flow
- 12.45
Balance Sheet
Genomma Lab Internacional SAB de CV has EUR 2.74B in cash and marketable securities with EUR 8.06B in debt, giving a net cash position of -EUR 5.32B billion.
- Cash & Marketable Securities
- EUR 2.74B
- Total Debt
- EUR 8.06B
- Net Cash
- -EUR 5.32B
- Net Cash Per Share
- -EUR 5.32
- Tangible Book Value Per Share
- EUR 6.30
Margins
Gross margin is 62.61%, with operating margin of 19.91%, and net profit margin of 9.96%.
- Gross Margin
- 62.61%
- Operating Margin
- 19.91%
- Pretax Margin
- 14.30%
- Net Profit Margin
- 9.96%
- EBITDA Margin
- 21.49%
- EBIT Margin
- 19.35%
Analyst Forecast
The average price target for Genomma Lab Internacional SAB de CV is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -0.21%
- EPS Growth Forecast
- 3.00%
